Urethritis screening

Urinary Tract Infections Main Page
Sexually Transmitted Diseases Main Page
Urethritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Urethritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT Scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Urethritis screening On the Web
Most recent articles
Most cited articles
Review articles
Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Urethritis screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA onUrethritis screening
CDC onUrethritis screening
Urethritis screeningin the news
Blogs onUrethritis screening
Directions to Hospitals Treating Urethritis
Risk calculators and risk factors for Urethritis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

High-risk individuals should be screened for sexually transmitted diseases. The U.S. Preventive Service Task Force (USPSTF) developed recommendations for the screening of for Chlamydia trachomatis and N. gonorrhea.

Screening

According to the U.S. Preventive Service Task Force (USPSTF), screening for sexually transmitted disease is recommended as outlined below for Chlamydia trachomatis and N. gonorrhea.

Chlamydia trachomatis
Population	Recommendations
Women	Sexually active women under 25 years of age Sexually active women aged 25 years and older if at increased risk Prior history of sexually transmitted infection A new sex partner More than one sex partner A sex partner with concurrent partners A sex partner who has a sexually transmitted infection Retest 3 months after treatment.
Men	Consider screening young men in high-prevalence clinical settings or in populations with a high burden of infection (e.g., men who have sex with men)
Pregnant women	All pregnant women under 25 years of age Pregnant women aged 25 years and older if at increased risk Retest during the third trimester for women under 25 years of age or at risk Pregnant women with chlamydial infection should have a test-of-cure 3-4 weeks after treatment and be retested within 3 months
Men Who have Sex With Men (MSM)	At least annually for sexually active MSM at sites of contact (urethra, rectum) regardless of condom use Every 3 to 6 months if at increased risk
HIV positive patients	For sexually active individuals, screen at first HIV evaluation and at least annually More frequent screening may be indicated depending on individual risk behaviors and local epidemiology

Neisseria Gonorrhea
Population	Recommendations
Women	Sexually active women under 25 years of age Sexually active women age 25 years and older if at increased risk Prior history of sexually transmitted infection A new sex partner More than one sex partner A sex partner with concurrent partners A sex partner who has a sexually transmitted infection Retest 3 months after treatment.
Men Who have Sex With Men (MSM)	At least annually for sexually active MSM at sites of contact (urethra, rectum, pharynx) regardless of condom use Every 3 to 6 months if at increased risk
Pregnant women	All pregnant women under 25 years of age and older women if at increased risk Retest 3 months after treatment
HIV positive patients	For sexually active individuals, screen at first HIV evaluation and at least annually More frequent screening may be indicated depending on individual risk behaviors and the local epidemiology